| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
TaiGen Biopharmaceuticals Holdings Limited (TWO: 4157)
4157 Technical Analysis
5
| As on 12th Mar 2025 4157 STOCK Price closed @ 11.10 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 14.99 & Strong Sell for SHORT-TERM with Stoploss of 14.82 we also expect STOCK to react on Following IMPORTANT LEVELS. |
4157STOCK Price
| Open | 11.00 | Change | Price | % |
| High | 11.15 | 1 Day | 0.10 | 0.91 |
| Low | 10.95 | 1 Week | -0.10 | -0.89 |
| Close | 11.10 | 1 Month | 0.40 | 3.74 |
| Volume | 479037 | 1 Year | -3.90 | -26.00 |
| 52 Week High 16.85 | 52 Week Low 10.70 | ||||
TWO Taiwan Most Active Stocks
| 4931 | 88.50 | 2.91% |
| 1815 | 31.90 | -2.60% |
| 3211 | 203.50 | 6.54% |
| 4303 | 69.30 | 1.91% |
| 4979 | 179.50 | 4.66% |
| 5439 | 160.50 | 0.31% |
| 6148 | 41.50 | -1.31% |
| 3260 | 92.50 | -0.54% |
| 2641 | 22.10 | -6.55% |
| 8096 | 62.90 | -3.23% |
TWO Taiwan Top Gainers Stocks
TWO Taiwan Top Losers Stocks
| 4157 Daily Charts |
4157 Intraday Charts |
Whats New @ Bazaartrend |
4157 Free Analysis |
|
|
4157 Important Levels Intraday
| RESISTANCE | 11.49 |
| RESISTANCE | 11.36 |
| RESISTANCE | 11.29 |
| RESISTANCE | 11.21 |
| SUPPORT | 10.99 |
| SUPPORT | 10.91 |
| SUPPORT | 10.84 |
| SUPPORT | 10.71 |
4157 Forecast March 2025
| 4th UP Forecast | 15.82 |
| 3rd UP Forecast | 14.31 |
| 2nd UP Forecast | 13.37 |
| 1st UP Forecast | 12.44 |
| 1st DOWN Forecast | 9.76 |
| 2nd DOWN Forecast | 8.83 |
| 3rd DOWN Forecast | 7.89 |
| 4th DOWN Forecast | 6.38 |
4157 Weekly Forecast
| 4th UP Forecast | 12.16 |
| 3rd UP Forecast | 11.82 |
| 2nd UP Forecast | 11.61 |
| 1st UP Forecast | 11.40 |
| 1st DOWN Forecast | 10.80 |
| 2nd DOWN Forecast | 10.59 |
| 3rd DOWN Forecast | 10.38 |
| 4th DOWN Forecast | 10.04 |
4157 Forecast2025
| 4th UP Forecast | 23.91 |
| 3rd UP Forecast | 19.8 |
| 2nd UP Forecast | 17.26 |
| 1st UP Forecast | 14.72 |
| 1st DOWN Forecast | 7.48 |
| 2nd DOWN Forecast | 4.94 |
| 3rd DOWN Forecast | 2.4 |
| 4th DOWN Forecast | -1.71 |
TaiGen Biopharmaceuticals Holdings Limited ( TWO Taiwan Symbol : 4157 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
4157 Business Profile
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for infectious diseases and other indications worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan. Address: No. 138, Xinming Road, Taipei, Taiwan, 11470
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service